Update on Vaccination Recommendations for Adults with HIV
Current HIV/AIDS Reports,
Год журнала:
2025,
Номер
22(1)
Опубликована: Фев. 20, 2025
Язык: Английский
“I’m Afraid to Put Any More of It Into My Body”: COVID-19 Vaccination and Booster Barriers and Facilitators Among People with HIV in South Carolina
AIDS and Behavior,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 3, 2025
Язык: Английский
Navigating Coronavirus Disease 2019 in Immunocompromised Populations
Infectious Disease Clinics of North America,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Determinants of COVID-19 Vaccine Uptake Among People Living with Human Immunodeficiency Virus
Journal of the International Association of Providers of AIDS Care (JIAPAC),
Год журнала:
2025,
Номер
24
Опубликована: Апрель 1, 2025
Background
Human
immunodeficiency
virus
(HIV)
cases
are
rising
in
Central
Asia
and
Kazakhstan.
People
living
with
HIV
(PLWH)
Kazakhstan
at
heightened
risk
of
severe
COVID-19.
We
conducted
a
study
to
evaluate
determinants
COVID-19
vaccine
uptake
among
PLWH
Methods
In
this
cross-sectional
study,
196
were
recruited
from
the
Almaty
City
AIDS
Center
(July
2022-January
2023).
used
logistic
regression
how
multilevel
factors
associated
Results
non-uptake
was
higher
stigma
scores
(AOR
=
1.08,
95%CI:1.02,1.16,
P
0.017),
lower
level
education
2.53,
95%CI:
1.04,6.17,
0.0412),
never
receiving
flu
15.64,
95%CI:3.66,66.89,
0.0002).
Participants
least
mild
anxiety
symptoms
0.15,
95%CI:0.03,0.64,
0.0107)
positive
attitude
towards
vaccination
0.79,
0.73,0.86,
<
0.0001)
less
likely
remain
unvaccinated
against
Conclusions
campaigns
should
be
tailored
for
incorporate
reduction
interventions
within
healthcare
settings.
Язык: Английский
Factors Associated with Vaccination Adequacy in People Living with HIV: A Cross-Sectional Study
Vaccines,
Год журнала:
2024,
Номер
12(9), С. 1003 - 1003
Опубликована: Сен. 1, 2024
People
living
with
HIV
(PLHIV)
are
at
greater
risk
of
illness
and
death
from
vaccine-preventable
diseases.
This
study
aimed
to
identify
the
predictors
associated
recommended
vaccination
schedule
for
this
group.
was
a
single-center
cross-sectional
conducted
in
large
Brazilian
municipality,
evaluating
statuses
645
PLHIV
nine
immunizers.
The
primary
outcome
adequacy
schedule.
status
assessed
diphtheria/tetanus,
hepatitis
B,
A,
measles/mumps/rubella,
yellow
fever,
13-
23-valent
pneumococcal,
meningococcal
C,
HPV
vaccines.
Those
who
had
received
all
vaccinations
accordance
established
by
government
time
assessment,
without
any
delays,
were
classified
as
having
an
“adequate
schedule”.
independent
variables
included
sociodemographic,
clinical–epidemiological,
social
vulnerability
factors,
analyzed
multiple
logistic
regression
adjusted
odds
ratios
(ORs)
95%
confidence
intervals
(95%
CIs).
Only
47
individuals
(7.3%)
adequate
vaccines
highest
rate
diphtheria
tetanus
(533;
82.6%),
one
lowest
measles/mumps/rubella
(MMR)
(243;
37.7%).
main
complete
age
group,
place
clinical
follow-up,
where
they
their
last
doses
Educational
interventions
health
professionals
needed
improve
coverage
Язык: Английский
COVID-19 Vaccination and Transient Increase in CD4/CD8 Cell Counts in People with HIV: Evidence from China
Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1365 - 1365
Опубликована: Дек. 3, 2024
Objectives:
Accumulating
evidence
has
confirmed
the
efficacy
and
safety
of
COVID-19
vaccines
against
SARS-CoV-2
infection.
However,
effect
vaccination
on
immuno-virological
parameters
in
people
with
HIV
(PWH)
is
uncertain.
Methods:
A
total
372
PWH
treated
at
Beijing
Ditan
Hospital
were
included.
Unvaccinated
matched
1:3
vaccinated
using
a
propensity
score
matching
algorithm.
Differences
markers
between
groups
analyzed.
The
Wilcoxon
signed
rank
test
was
used
to
for
changes
CD4
CD8
counts
viral
load
over
two
months
around
vaccination.
In
addition,
we
investigated
long-term
HIV-related
different
dose
entire
population.
Results:
Vaccinated
had
higher
CD4/CD8
ratio
(0.64
(0.49,
0.78)
vs.
0.80
(0.56,
1.03),
p
=
0.037)
than
unvaccinated
within
two-month
window
after
third
dose.
There
337
who
received
vaccination,
73.9%
(n
249)
three
doses
vaccine.
We
observed
transient
increase
count
especially
second
(CD4
count:
583.5
(428.5,
706.8)
618.0
(452.0,
744.0),
0.018;
ratio:
0.70
(0.50,
0.91)
0.71
(0.53,
0.96),
<
0.001))
575.5
(435.5,
717.0)
577.5
(440.8,
754.8),
0.001;
(0.52,
0.93)
0.79
1.00),
0.001)).
Recent
ratios
lower
but
remained
before
PWH.
no
negative
load.
Conclusions:
enhanced
cellular
immune
response
induced
by
may
diminish
time
return
normal
levels.
adverse
Язык: Английский